CHIRURGICKÁ LÉČBA MELANOMU

Autoři: K. Novotná ¹; M. Arenbergerová ²; J. Miletín ¹; J. Kníže ¹; V. Šandera ¹; K. Schwarzmannová ¹; J. Bayer ¹; A. Sukop ¹
Působiště autorů: Department of Plastic Surgery, 3rd Faculty of Medicine, Charles University, Královské Vinohrady University Hospital, Prague, Czech Republic ¹; Department of Dermatology, 3rd Faculty of Medicine, Charles University, Královské Vinohrady University Hospital, Prague, Czech Republic ²
Vyšlo v časopise: ACTA CHIRURGIAE PLASTICAE, 59, 3-4, 2017, pp. 149-155

Zdroje

1. Brown DL, Borschel GH, Levi B. Michigan manual of plastic surgery. Lippincott Williams & Wilkins, 2014.

2. Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol. 2014 Jan;170(1):20-30.

3. Cafardi, Jennifer. The manual of dermatology. Springer Science & Business Media, 2012.

4. Johnston, Ronald. Weedon’s Skin Pathology Essentials E-Book. Elsevier Health Sciences, 2016.

5. Kružicová Z. Maligní melanom. Postgraduální medicína. [online]. 2010 [cit. 2016-06-15]. Available from: http://zdravi.euro.cz/clanek/postgradualni-medicina/maligni-melanom-450829

6. Kasprzak JM, Xu YG. Diagnosis and management of lentigo maligna: a review. Drugs Context. 2015 May 29;4 : 212281.

7. Wilson JB, Walling HW, Scupham RK, Bean AK, Ceilley RI, Goetz KE. Staged Excision for Lentigo Maligna and Lentigo Maligna Melanoma: Analysis of Surgical Margins and Long-term Recurrence in 68 Cases from a Single Practice. J Clin Aesthet Dermatol. 2016 Jun;9(6):25-30.

8. Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol. 2005;6(3):151-64.

9. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline –⁠ Update 2016. Eur J Cancer. 2016 Aug;63 : 201-17.

10. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012;5(8):739-53.

11. Intraocular (Uveal) Melanoma Treatment (PDQ^®) –⁠ Health Professional Version. In: National Cancer Institute [online]. 2015 [cit. 2016-6-15]. Available from: https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq

12. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan;20(1):1-17.DOI: 10.1016/j.soc.2010.09.007. ISSN 1055-3207.

13. Povýšil C., Šteiner I. Speciální patologie. Druhé, doplněné a přepracované vydání. Praha: Galén, 2007.

14. Hayes AJ, Clark MA, Harries M, Thomas JM. Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg. 2004 Jun;91(6):673-82.

15. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012 : 647684.

16. Tan WW. Malignant melanoma. In: Medscape [online]. 2016 [cit. 2016-6-15]. Available from: http://emedicine.medscape.com/article/280245-overview

17. Grotz TE, Markovic SN, Erickson LA et al. Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma. Mayo Clin Proc. 2011 Jun;86(6):522-8.

18. Bichakjian CK, Halpern AC, Johnson TM et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011 Nov;65(5):1032-47.

19. Balch ChM, Charles M, Thompson JF, Faries MB. The Clinical Value of Sentinel Lymph Node Biopsy In Melanoma Staging, Regional Disease Control, and Survival: The Melanoma Letter. Summer 2015, Vol. 33, No. 1. In: Skin Cancer Foundation [online]. 2015 [cit. 2016-6-15]. Available from: http://www.skincancer.org/publications/the-melanoma-letter/summer-2015-vol-33-no-1/sentinel

20. Lloyd MS, Topping A, Allan R, Powell B. Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma. Br J Plast Surg. 2004 Dec;57(8):725-7.

21. Wong SL, Balch CM, Hurley P et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012 Aug 10;30(23):2912-8.

22. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classifica-tion. J Clin Oncol. 2009 Dec 20;27(36):6199-206.

23. Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T. 2012 Sep;37(9):503-30.

24. Carbognin L, Pilotto S, Milella M et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015 Jun 18;10(6):e0130142.

25. Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field. Ann Transl Med. 2016 Jul;4(14):269.

26. Krajsová I. Kožní melanom: diagnostika, léčba a pooperační sledování. Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie [serial online]. November 2012;87(5):163-175.

27. Špaček M, Mitáš P, Lacina L. Cytostatická hypertermická perfuze izolované končetiny (HILP) ve VFN. Rozhl. Chir. 2011, 90(1), 62-66.

28. Simone MD, Vaira M. Hyperthermic Isolated Limb Perfusion. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000–2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6461/

29. Khan MK, Khan N, Almasan A, Macklis R. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther. 2011;4 : 137-48